Harvard Medicine Magazine · Jul 2026
Harvard Medicine Magazine described the field’s progress and noted eGenesis’s ongoing kidney-trial collaboration with Mass General.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
eGenesis is a clinical-stage biotechnology company developing CRISPR-enabled xenotransplantation platforms to create human-compatible pig organs for transplant, with a lead program focused on the EGEN-2784 porcine kidney for patients with end-stage kidney disease.
Primary product
EGEN-2784 genetically engineered porcine kidney
Founded
2015
Headquarters
Cambridge, Massachusetts, United States
Team size
51-200
Work style
Flexible
Industry
Biotechnology Research
Sub-industry
Genome engineering / xenotransplantation
Offices
300 Technology Sq, Cambridge, MA 02139 (HQ)
101 Cambridgepark Drive, Suite 200, Cambridge, Massachusetts, United States
101 Cambridgepark Drive, Cambridge, MA 02140, United States
Cambridge, Massachusetts, United States
Funding
People & investors
Leadership
President & Chief Executive Officer
Chief Commercial Officer
Chief Financial Officer
Work & culture
Mission-driven and patient-centric, with stated core values of innovation, collaboration, compassion, resilience, and passion; hiring materials emphasize teamwork across research, medical, and business functions.
Work style
Flexible
Compensation
No company-wide compensation policy was disclosed publicly. Public job ads show role-level salary signals such as about $105.6k-$158.4k for Senior Clinical Research Associate and $175k-$226k for Associate Director, Clinical Science.
Product & market
Differentiators
- —Multiplex gene editing of donor pigs
- —Three classes of edits to improve compatibility and safety
- —Inactivation of porcine retroviruses to reduce viral risk
- —Lead clinical program already in human-expanded-access use
- —Focus on human-compatible organs for kidney, liver, and heart indications
Technology
Power BI
PostgreSQL
Snowplow
Benchling
Scale & contact
Estimated revenue
$20M-$30M
Latest news
BioSpace · Jun 2026
Announced new CFO and CCO appointments as eGenesis moved deeper into clinical development and commercialization planning.
Fast Company · Mar 2026
Profiled eGenesis as a top innovator, highlighting its gene-edited pig kidneys already used in human transplant attempts and the company's path toward trials and eventual approval.
eGenesis · Mar 2026
eGenesis was named Fast Company’s No. 1 biotech company and No. 34 overall on the 2026 Most Innovative Companies list.